| Literature DB >> 24414342 |
Å Håkansson1, N Tormo-Badia, A Baridi, J Xu, G Molin, M-L Hagslätt, C Karlsson, B Jeppsson, C M Cilio, S Ahrné.
Abstract
Ulcerative colitis (UC) is characterized by chronic inflammation of the colonic mucosa. Administration of dextran sulfate sodium (DSS) to animals is a frequently used model to mimic human colitis. Deregulation of the immune response to the enteric microflora or pathogens as well as increased intestinal permeability have been proposed as disease-driving mechanisms. To enlarge the understanding of the pathogenesis, we have studied the effect of DSS on the immune system and gut microbiota in mice. Intestinal inflammation was verified through histological evaluation and myeloperoxidase activity. Immunological changes were assessed by flow cytometry in spleen, Peyer's patches and mesenteric lymph nodes and through multiplex cytokine profiling. In addition, quantification of the total amount of bacteria on colonic mucosa as well as the total amount of lactobacilli, Akkermansia, Desulfovibrio and Enterobacteriaceae was performed by the use of quantitative PCR. Diversity and community structure were analysed by terminal restriction fragment length polymorphism (T-RFLP) patterns, and principal component analysis was utilized on immunological and T-RFLP patterns. DSS-induced colitis show clinical and histological similarities to UC. The composition of the colonic microflora was profoundly changed and correlated with several alterations of the immune system. The results demonstrate a relationship between multiple immunological changes and alterations of the gut microbiota after DSS administration. These data highlight and improve the definition of the immunological basis of the disease and suggest a role for dysregulation of the gut microbiota in the pathogenesis of colitis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24414342 PMCID: PMC4308640 DOI: 10.1007/s10238-013-0270-5
Source DB: PubMed Journal: Clin Exp Med ISSN: 1591-8890 Impact factor: 3.984
Primers used in qPCR to amplify four target regions
| Name | Sequence (5′–3′) | Target group | Amplicon size (bp) | Template DNA | Annealing term (°C) | References |
|---|---|---|---|---|---|---|
| Lact-F | AGCAGTAGGGA ATCTTCCA (19) |
| 341 |
| 61 | Walter et al. [ |
| Lact-R | CACCGCTACAC ATGGAG (17) | Heilig et al. [ | ||||
| Uni331-F | TCCTACGGGAG GCAGCAGT (19) | Total bacteria | 466 |
| 58 | Nadkarni et al. [ |
| Uni797-R | GGACTACCAGG GTATCTAATCCTGTT (26) | |||||
| Ecol457-F | CATTGACGTTAC CCGCAGAAGAAGC (25) |
| 195 |
| 60 | Bartosch et al. [ |
| Ecol652-R | CTCTACGAGACT CAAGCTTGC (21) | |||||
| AMI-F | CAGCACGTGAA GGTGGGGGACC (20) |
| 327 |
| 60 | Collado et al. [ |
| AM2-R | CCTTGCGGTTGG CTTCAGAT (20) | |||||
| DSV691-F | CCGTAGATATCT GGAGGAACATCAG |
| 135 |
| 62 | Fite et al. [ |
| DSV826-R | ACATCTAGCATC CATCGTTTACAGC |
Fig. 6Comparison of bacterial populations determined by qPCR. *P < 0.05 and **P < 0.01 compared to the NC group
Feed intake, body weight change, DAI, caecal wet/dry weight, colon length and colon wet weight in the normal control group (NC) and in the group receiving DSS (DSS)
| NC | DSS | |
|---|---|---|
| Total feed intake (g) | 23.0 (21.1 to 23.6) (n = 9) | 16.5 (15.3 to 17.3) (n = 8)*** |
| Body weight change (g) | 0.3 (−0.5 to 1.0) (n = 10) | −4.0(−5.5 to (−3.0)) (n = 10)*** |
| Body weight change (g/g feed) | 0.02 (−0.03 to 0.04) (n = 9) | −0.3(−0.4 to (−0.2)) (n = 8)*** |
| Disease activity index (day 7) | 0.0 (0.0 to 0.3) (n = 10) | 2.8 (2.3 to 3.0)(n = 10)*** |
| Caecal wet/dry weight (g) | 3.7 (3.3 to 4.5) (n = 10) | 5.8 (4.7 to 6.0) (n = 10)*** |
| Colon length (cm) | 7.9 (7.5 to 8.2) (n = 10) | 6.3 (5.9 to 7.0) (n = 10)*** |
| Colon wet weight (g) | 0.18 (0.15 to 0.20) (n = 9) | 0.29 (0.24 to 0.30) (n = 9)*** |
Data are expressed as median values, range is presented within brackets. Asterisks indicate statistically significant difference from NC group: ***p < 0.001
Concentrations (pg/ml) of cytokines/chemokines in serum
| Serum | |||||
|---|---|---|---|---|---|
| Cytokine/chemokine | Group | n | Median | 25–75 % |
|
| KC | NC | 7 | 27.57 | 7.18–50.57 | |
| DSS | 9 | 669.63 | 376.73–2244.24 | 0.006** | |
| IL-6 | NC | 7 | 0.67 | 0.67–17.57 | |
| DSS | 9 | 74.13 | 42.35–85.00 | 0.008** | |
| IL-17 | NC | 7 | 0.91 | 0.54–1.32 | |
| DSS | 9 | 3.05 | 1.87–460 | 0.017* | |
| TNF-α | NC | 7 | 0.81 | 0.81–2.03 | |
| DSS | 9 | 3.54 | 0.057 | ||
| IL-5 | NC | 7 | 6.80 | 4.87–12.78 | |
| DSS | 9 | 4.12 | 0.169 | ||
| IL-4 | NC | 7 | 0.93 | 0.73–0.98 | |
| DSS | 9 | 0.73 | 0.220 | ||
| IL-12 | NC | 7 | 46.84 | 2.46–75.03 | |
| DSS | 9 | 5.61 | 0315 | ||
| IL-2 | NC | 7 | 1.06 | 1.06–4.00 | |
| DSS | 9 | 1.53 | 0.396 | ||
| IL-Iβ | NC | 7 | 2.31 | 2.31–3.16 | |
| DSS | 9 | 2.60 | 0.523 | ||
| IFN-γ | NC | 7 | 17.12 | 0.81–27.59 | |
| DSS | 9 | 3.51 | 0.711 | ||
| IL-10 | NC | 7 | 3.50 | 1.82–21.83 | |
| DSS | 9 | 5.0 | 0.916 | ||
** P < 0.01 and * P < 0.05 compared to NC group
aMann-Whitney U test.
Fig. 2Statistical differences of percentage gated cells from Peyer′s patches. P values between the NC group and the DSS group are mentioned in the graph. Outliers are shown as circle and extreme values are shown as asterisk
Fig. 3Statistical differences of percentage gated cells from mesenteric lymph nodes. P values between the NC group and the DSS group are mentioned in the graph. Outliers are shown as ° and extreme values are shown as asterisk
Fig. 4Statistical differences of percentage gated cells from spleen. P values between the NC group and the DSS group are mentioned in the graph. Outliers are shown as circle and extreme values are shown as asterisk
Fig. 1Histological analysis of intestinal mucosa. a Normal crypt architecture and the absence of inflammation in colonic mucosa (NC group). b Grade 2 lesion of colonic mucosa (DSS group). c Grade 3 lesion of colonic mucosa (DSS group)
Results of FACS analysis showing median with minimum and maximum values within parenthesis
| Cells | Group | Mesenteric lymph nodes | Peyer’s patches | Spleen | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Median (min–max) |
| n | Median (min–max) |
| n | Median (min–max) |
|
| ||
| T cells (CD3+), T-helper (CD4+), Cytotoxic T cells (CD8+) and B cells (B220+) | |||||||||||
| CD3+ | DSS | 9 | 40.6 (35.4–62.7) | 8 | 28.9 (19.7–45.1) | 10 | 30.5 (24.6–43.5) | 0.034* | |||
| NC | 10 | 59.2 (21.4–73.4) | 0.060 | 9 | 18.6 (14.7–21.4) | 0.001** | 10 | 31.0 (28.8–35.7) | 0.31 | 0.001** | |
| CD4+ | DSS | 9 | 55.4 (51.9–57.5) | 8 | 68.9 (59.0–72.8) | 10 | 57.8 (55.9–62.7) | 0.002** | |||
| NC | 10 | 56.9 (51.0–75.7) | 0.19 | 9 | 75.7 (70.9–79.1) | 0.003** | 10 | 58.0 (54.6–65.2) | 0.65 | 0.002** | |
| CD8+ | DSS | 9 | 42.0 (38.9–45.0) | 8 | 26.0 (22.1–29.2) | 10 | 37.2 (33.0–40.0) | 0.001** | |||
| NC | 10 | 40.1 (19.8–46.5) | 0.22 | 9 | 21.0 (18.3–24.1) | 0.012* | 10 | 36.3 (28.7–39.4) | 0.70 | 0.001** | |
| B220+ | DSS | 9 | 54.5 (33.1–60.0) | 8 | 66.1 (9.53–76.9) | 10 | 63.2 (46.9–66.3) | 0.20 | |||
| NC | 10 | 36.3 (24.2–76.8) | 0.12 | 9 | 79.2 (14.5–83.9) | 0.054 | 10 | 60.7 (51.3–62.2) | 0.16 | 0.099* | |
| Recruited T cells (CCR9+CD4+/CD8+) and activated T cells (CD4+/CD8+CD69-/CD69+) | |||||||||||
| CCR9+CD4+ | DSS | 9 | 1.22 (0.33–8.72) | 8 | 1.43 (0.73–9.74) | 10 | 0.70 (0.22–1.03) | 0.008** | |||
| NC | 10 | 1.32 (0.34–6.28) | 0.65 | 9 | 0.75 (0.34–1.44) | 0.012* | 10 | 0.44 (0.20–1.71) | 0.45 | 0.011* | |
| CD4+CD69- | DSS | 9 | 49.0 (37.1–61.2) | 8 | 30.6 (12.7–45.0) | 10 | 63.2 (44.7–76.9) | 0.002** | |||
| NC | 10 | 52.7 (30.6–80.6) | 0.87 | 9 | 21.5 (15.7–80.6) | 0.15 | 10 | 58.7 (26.3–74.5) | 0.50 | 0.008** | |
| CD4+CD69+ | DSS | 9 | 51.0 (34.3–62.9) | 8 | 69.4 (55.0–87.3) | 10 | 36.8 (23.1–55.3) | 0.002** | |||
| NC | 10 | 47.3 (9.00–69.4) | 0.94 | 9 | 77.3 (9.00–84.3) | 0.39 | 10 | 39.7 (25.5–73.7) | 0.65 | 0.008** | |
| CCR9+CD8+ | DSS | 9 | 0.80 (0.32–2.31) | 8 | 1.23 (0.71–3.00) | 10 | 0.42 (0.18–1.48) | 0.044* | |||
| NC | 10 | 0.78 (0.09–2.32) | 0.62 | 9 | 0.51 (0.09–0.77) | 0.001** | 10 | 0.40 (0.15–1.80) | 0.82 | 0.027* | |
| CD8+CD69- | DSS | 9 | 57.3 (44.4–80.6) | 8 | 26.2 (5.88–69.4) | 10 | 76.1 (66.6–84.9) | 0.011* | |||
| NC | 10 | 61.8 (17.6–82.4) | 0.68 | 9 | 37.6 (17.6–56.8) | 0.50 | 10 | 78.2 (57.4–89.9) | 0.60 | 0.001** | |
| CD8+CD69+ | DSS | 9 | 40.2 (11.5–55.5) | 8 | 72.2 (30.6–94.1) | 10 | 21.7 (15.1–28.7) | 0.002** | |||
| NC | 10 | 38.2 (17.6–82.4) | 0.68 | 9 | 54.0 (37.9–82.4) | 0.21 | 10 | 21.5 (10.1–42.6) | 0.70 | 0.001** | |
| Monocytes (CD11b+CD11c+), macrophages (CD11b+CD11c-) dentritics (CD11b-C11c+) and bacteria induced activation (CD11c+TLR4+) | |||||||||||
| CDllb+CDllc+ | DSS | 9 | 22.9 (13.5–50.8) | 8 | 12.0 (2.15–27.6) | 10 | 11.2 (6.44–26.2) | 0.002** | |||
| NC | 10 | 9.12 (1.01–18.9) | 0.003** | 9 | 11.3 (1.49–16.7) | 0.77 | 10 | 10.8 (3.68–16.9) | 0.60 | 0.64 | |
| CD1lb+CDllc- | DSS | 9 | 10.78 (5.74–17.81) | – | – | – | – | – | |||
| NC | 9 | 8.59 (2.47–15.73) | 0.31 | – | – | – | – | – | – | – | |
| CDllb-CDllc+ | DSS | 9 | 5.23 (2.12–16.75) | – | – | – | – | – | |||
| NC | 9 | 8.57 (4.65–15.25) | 0.058 | – | – | – | – | – | – | – | |
| CDllc+TLR4+ | DSS | 9 | 14.2 (2.12–21.4) | 8 | 5.57 (0.88–9.76) | 10 | 18.5 (2.39–35.0) | 0.030* | |||
| NC | 10 | 5.62 (0.30–16.4) | 0.018** | 9 | 3.44 (2.02–8.09) | 0.63 | 10 | 23.2 (1.80–38.0) | 0.88 | 0.045* | |
| Intracellular (CD4+CD25+) | |||||||||||
| CD4+CD25+FoxP3+ | DSS | 9 | 15.5 (14.3–18.4) | 7 | 12.7(10.4–15.8) | 10 | 17.6 (5.13–21.2) | 0.028* | |||
| NC | 10 | 8.51 (4.52–16.1) | 0.004** | 9 | 11.6 (7.88–14.4) | 0.10 | 10 | 16.4 (12.7–22.6) | 0.23 | 0.004** | |
| CD4+CD25+CD69+FoxP3+ | DSS | 9 | 37.6 (14.5^2.6) | 8 | 36.5 (29.3–52.0) | 10 | 29.1 (21.4–32.1) | 0.010* | |||
| NC | 10 | 13.6 (3.29–45.6) | 0.034* | 9 | 39.0 (3.99–51.3) | 0.92 | 10 | 27.3 (23.4–36.4) | 0.50 | 0.032* | |
| CD4+CD25+CTLA4+FoxP3+ | DSS | 9 | 70.0 (61.0–81.6) | 8 | 62.8 (51.0–73.7) | 10 | 73.1 (57.7–81.6) | 0.010* | |||
| NC | 10 | 34.4 (7.84–76.1) | 0.003** | 9 | 44.7 (9.88–70.6) | 0.009** | 10 | 47.0 (25.8–78.7) | 0.005 | 0.72 | |
| Regulatory T cells (CD4+/CD8+CD25+) and NK cells (CD4+/CD8+CD49b+) | |||||||||||
| CD4+CD25+ | DSS | 9 | 17.2 (6.06–25.6) | 8 | 9.34 (2.29–21.1) | 10 | 16.7 (9.86–20.0) | 0.093 | |||
| NC | 10 | 13.9 (10.5–21.9) | 0.22 | 9 | 11.0 (5.37–14.0) | 0.21 | 10 | 15.3 (8.08–19.6) | 0.15 | 0.004** | |
| CD8+CD25+ | DSS | 9 | 3.10 (1.14–6.81) | 8 | 6.04 (1.77–15.1) | 10 | 2.24 (0.94–5.61) | 0.072 | |||
| NC | 10 | 2.20 (0.69–14.0) | 0.68 | 9 | 4.41 (2.92–6.53) | 0.44 | 10 | 2.64 (1.24–4.30) | 0.36 | 0.032* | |
| CD4+CD49b+ | DSS | 9 | 1.13 (0.79–2.10) | 8 | 2.12 (1.10–.89) | 10 | 4.46 (2.62–6.11) | 0.011* | |||
| NC | 10 | 0.88 (0.45–1.98) | 0.37 | 9 | 1.48 (0.92–2.18) | 0.054 | 10 | 3.48 (1.48–5.71) | 0.049 | <0.001*** | |
| CD8+CD49b+ | DSS | 9 | 1.15 (0.55–1.35) | 8 | 4.70 (2.19–17.3) | 10 | 2.36 (0.92–3.08) | 0.001** | |||
| NC | 10 | 1.05 (0.73–3.44) | 0.87 | 9 | 2.93 (1.47–.97) | 0.054 | 10 | 2.26 (0.34–3.27) | 0.76 | 0.062 | |
| Number of cells | DSS | 8 | 26.2 (13.9–69.0) | 8 | 4.25 (1.00–7.00) | 8 | 188 (37.5–371) | – | |||
| NC | 8 | 7.95 (3.30–23.0) | 0.002** | 8 | 10.6 (0.37–29.8) | 0.021* | 8 | 189 (44.0–333) | 0.88 | – | |
*P < 0.05, ** P < 0.01 and *** P < 0.001 between groups (Pa) or within groups (Pb)
aComparison between groups by means of the Mann–Whitney U test
bComparison between organs within each group by means of the Friedman’s test
Size of T-RFs detected in the samples from the two groups that have significantly different frequency of occurrence
| T | NC | DSS | Significance |
|---|---|---|---|
| 88.76 | 6 | 1 |
|
| 93.59 | 0 | 8 | P < 0.001*** |
| 94.73 | 0 | 4 |
|
| 141.29 | 0 | 4 |
|
| 156.03 | 0 | 4 |
|
| 183.79 | 6 | 0 |
|
| 200.52 | 0 | 4 |
|
| 203.83 | 8 | 1 |
|
| 298.71 | 0 | 4 |
|
| 489.83 | 0 | 4 |
|
| 543.55 | 0 | 4 |
|
* P < 0.05, ** P < 0.01 and *** P < 0.001 between NC DSS groups
Fig. 5PCA 3D score scatter plot of T-RFLP data obtained from MspI digestion
Fig. 7PCA score scatter plot of T-RFLP data obtained from MspI digestion together with flow cytometry data measured from mesenteric lymph nodes. filled circles represent animals from the NC group, and open circles represent those from the DSS group